Paul Kellam is the Professor of Virus Genomics at Imperial College London and Vice President of infectious diseases & vaccines at Kymab Ltd, UK. He has published over 200 primary research papers, reviews, book chapters and patents. Paul Is a Fellow of the American Academy of Microbiology and Council Member of the UK Microbiology Society.
Paul’s scientific career has spanned the pharmaceutical industry, at the Wellcome Foundation Ltd and Kymab Ltd and academia, where Paul was the Virus Genomics lead at the Wellcome Trust Sanger Institute and a Professor of Virology at UCL.
Paul’s research has identified how HIV develops resistance to antiviral drugs and has identified the first influenza disease severity gene in people hospitalised with influenza virus. His laboratory produced the virus genome analysis of the Middle East Respiratory Syndrome Coronavirus (MERS CoV) outbreaks working with the Department of Health in Saudi Arabia, showing that the transmission pattern of the virus was consistent with multiple transfer events from an animal reservoir and contributing to the identification of camels as the animal reservoir. His laboratory contributed to the international Ebola virus genome analysis to help the WHO control the outbreak and to show the factors influencing virus transmission.
In 2016 Paul became the Professor of Virus Genomics at Imperial College London and the Vice President of Infectious Diseases & Vaccines at Kymab Ltd. The Imperial College laboratory is continuing its research theme of investigating virus and host genetic variation during infection. At Kymab Pauls’ work is focusing on using the Kymouse to develop therapeutic antibody treatments of infectious diseases and to further advance vaccine research.
et al., 2020, Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2, Cell, Vol:183, ISSN:0092-8674, Pages:1367-1382.e17
et al., 2020, Mapping of HIV-1C Transmission Networks Reveals Extensive Spread of Viral Lineages Across Villages in Botswana Treatment-as-Prevention Trial, Journal of Infectious Diseases, Vol:222, ISSN:0022-1899, Pages:1670-1680
et al., 2020, Scientific consensus on the COVID-19 pandemic: we need to act now, Lancet, Vol:396, ISSN:0140-6736, Pages:E71-E72
et al., 2020, Generation and Characterization of Typhoid Toxin-Neutralizing Human Monoclonal Antibodies., Infect Immun, Vol:88
et al., 2020, Interferon-induced Protein-44 and Interferon-induced Protein 44-like restrict replication of Respiratory Syncytial Virus, Journal of Virology, Vol:94, ISSN:0022-538X, Pages:1-15